Early mobilization in critically ill patients has been shown to prevent bed-rest-associated morbidity. Reported reasons for not mobilizing patients, thereby excluding or delaying such intervention, are diverse and comprise safety considerations high-risk with multiple organ support systems. This study sought demonstrate that early performed within the first 24 h of ICU admission proves be feasible well tolerated vast majority patients.

Abstract Purpose [ 18 F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and quantification of in vivo cerebral tauopathy Alzheimer’s disease (AD). Given that neurological symptoms are better explained by topography rather than nature brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with spatial extent intensity tau-PET signal, as measured standard uptake value ratio (SUVr). Methods F]MK6240 data from...

Alzheimer's disease (AD) is characterized by amyloid beta (Aβ) plaques and hyperphosphorylated tau in the brain. Aβ precede cognitive impairments can be detected through amyloid-positron emission tomography (PET) or cerebrospinal fluid (CSF). Assessing plasma Aβ42/Aβ40 ratio seems promising for non-invasive cost-effective detection of brain accumulation. This approach involves some challenges, including accuracy blood-based biomarker measurements establishment clear, standardized thresholds...

Early Alzheimer's disease diagnosis is crucial for preventive therapy development. Standard neuropsychological evaluation does not identify clinically normal individuals with brain amyloidosis, the first stage of pathology, defined as preclinical disease. Spatial navigation assessment, in particular path integration, appears promising to detect symptoms, medial temporal lobe plays a key role and cortical region affected by tau pathology. We have conducted cross-sectional study. related...

ABSTRACT Introduction Second‐generation tau‐PET tracers like [ 18 F]MK‐6240 are increasingly used both for diagnosing and quantifying Alzheimer's Disease (AD) tauopathy. However, while has demonstrated excellent sensitivity AD tauopathy, data assessing its specificity binding in non‐AD tauopathies still scarce. Methods Participants were assigned to exclusive categorical diagnoses based on their amyloid (Aβ) cognitive status. We quantified mesiotemporal (MTL) neocortical signal 28 Aβ−...

Abstract INTRODUCTION Magnetic resonance imaging (MRI) segmentation algorithms make it possible to study detailed medial temporal lobe (MTL) substructures as hippocampal subfields and amygdala subnuclei, offering opportunities develop biomarkers for preclinical Alzheimer's disease (AD). METHODS We identified the MTL significantly associated with tau‐positron emission tomography (PET) signal in 581 non‐demented individuals from Disease Neuroimaging Initiative (ADNI‐3). confirmed our results...

Essential tremor (ET), a movement disorder characterized by involuntary oscillations of the limbs during movement, remains to date not well understood. It has been recently suggested that originates from impaired delay compensation, affecting representation and online control. Here we tested this hypothesis directly with 24 ET patients (14 female; 10 male) 28 neurologically intact (NI) human volunteers (17 11 in an upper limb postural perturbation task. After maintaining their hand visual...

Background: Alzheimer’s disease (AD) pathology can be disclosed in vivo using amyloid and tau imaging, unlike non-AD neuropathologies for which no specific markers exist. Objective: We aimed to compare brain hypometabolism tauopathy unveil pathologies. Methods: Sixty-one patients presenting cognitive complaints (age 48–90), including 32 with positive AD biomarkers (52%), performed [18F]-Fluorodeoxyglucose (FDG)-PET (brain metabolism) [18F]-MK-6240-PET (tau). normalized these images data from...

Abstract Essential tremor (ET), a movement disorder characterized by involuntary oscillations of the limbs during movement, remains to date not well understood. It has been recently suggested that originates from impaired delay compensation, affecting representation and online control. Here we tested this hypothesis directly with ET patients (N=24) neurologically intact (NI) volunteers (N=28) in an upper limb postural perturbation task. After maintaining their hand visual target,...

Abstract Background In AD, tauopathy and atrophy start in the mesiotemporal lobe, including amygdala‐hippocampal complex. Until recently, subnuclei subfields within these structures were indistinguishable in‐vivo. FreeSurfer 7.0 now enables their segmentation. Our goal was to study hippocampal amygdala subregions’ preclinical AD assess whether specific subregion could indicate early at stage. Methods We conducted an exploratory ADNI3 cohort 144 amyloid‐positive cognitively‐normal adults...

Abstract Background The entorhinal cortex (EC) is the first cortical region affected by tauopathy in Alzheimer’s disease (AD) and implicated path integration. In early stages of AD, integration deficits could be present, even before overt memory deficits. Furthermore, are found among older individuals at risk for such as APOE ε4 carriers. We investigated whether this deficit was related to AD pathology or genotype using a pure task, “Apple Game” (Bierbrauer et al. 2020). Method Participants...

Abstract Background Alzheimer’s disease (AD) is associated with cognitive impairment, including spatial disorientation. Disorientation may be an early indicator of AD because navigation relies on entorhinal cortex, the first cortical region affected by pathology. To test hypothesis that declines in preclinical AD, we investigated age and genotype effects a virtual path integration task, "Apple Game" (Bierbrauer et al. 2020). Method Participants navigated field had to drop basket their...

Abstract INTRODUCTION Amyloid-β (Aβ) and tau are brain hallmarks of Alzheimer’s disease (AD) also present in blood as soluble biomarkers or encapsulated extracellular vesicles (EVs). Our goal was to assess how plasma AD pathology correlate with number content EVs. METHODS Single-molecule enzyme-linked assays were used quantify Aβ42/40 samples neurally-derived EVs (NDEVs) from a cohort APOE ε4– ε4+ cognitively normal individuals (CN) patients. RESULTS Soluble ratio is decreased patients...

<title>Abstract</title> Background Early Alzheimer’s disease diagnosis is crucial for preventive therapy development. Standard neuropsychological evaluation does not identify clinically normal individuals with brain amyloidosis, the first stage of pathology, defined as preclinical disease. Spatial navigation assessment, in particular path integration, appears promising to detect symptoms, medial temporal lobe plays a key role and cortical region affected by tau pathology. Methods We have...

Abstract Background In AD, tauopathy and atrophy start in the mesiotemporal lobe, including amygdala‐hippocampal complex. Until recently, subnuclei subfields within these structures were indistinguishable in‐vivo. FreeSurfer 7.0 now enables their segmentation. Our goal was to study hippocampal amygdala subregions’ preclinical AD assess whether specific subregion could indicate early at stage. Methods We conducted an exploratory ADNI3 cohort 144 amyloid‐positive cognitively‐normal adults...

Abstract Background Semantic processing relies on temporal brain regions, including medial lobe (MTL) structures, that are the first to be affected by tau pathology in Alzheimer’s disease (AD). A widely used task assess semantic memory is category fluency. Performance this was demonstrated impaired since prodromal stage of AD and associated structural integrity MTL. However, associations between fluency measures MTL burden have been rarely explored at early stages disease. Method...

Abstract Background Amyloid-β (Aβ) and tau are brain hallmarks of Alzheimer’s disease (AD), also present in blood as soluble biomarkers or encapsulated extracellular vesicles (EVs). Our goal was to assess how plasma AD pathology correlate with the number content EVs. Methods Single-molecule enzyme-linked assays were used quantify Aβ42/40 samples neurally-derived EVs (NDEVs) from a cohort APOE ε4– ( n = 168) ε4+ 68) cognitively normal individuals patients 55). The ratio CD56 (Neuronal...

Abstract Background The medial temporal lobe (MTL) is the first cortical region affected by tauopathy in Alzheimer’s disease (AD) and implicated spatial orientation. In early AD stages, navigation deficits, including path integration could be present, even before memory deficits. We investigated whether these deficits were related to pathology (amyloidosis and/or tauopathy) using a task, “Apple Game”. Method During participants navigated through virtual arena asked return starting location...

Abstract Background The ability to discriminate very similar objects by implementing the binding between their multiple features is assumed be supported medial temporal lobe (MTL). MTL first brain region that shows abnormal tau accumulation in Alzheimer’s disease (AD). However, whether impaired since preclinical stage of AD and relates burden not well‐established. Method We included 35 amyloid‐negative cognitively normal individuals (Aβ‐CN), 16 amyloid‐positive CN (Aβ+CN) 17 Aβ+ with Mild...

Abstract Background The recent development of positron emission tomography (PET) radiotracers for tau aggregates allows quantifying the regional burden in‐vivo . We aimed to investigate associations between tauopathy and episodic memory outcomes in AD spectrum from clinically normal dementia stage. Method recruited 111 participants 2019 2023 at Memory Clinic Saint‐Luc University Hospital. Each participant underwent [F18]‐MK6240 tau‐PET, 3DT1 MRI, cognitive assessment, either lumbar puncture...

Alzheimer&amp;#039;s disease (AD) is characterized by abnormal amyloid beta (Aβ) plaques and hyperphosphorylated tau in the brain. Aβ precede cognitive impairments can be detected through amyloid-PET or cerebrospinal fluid (CSF). Assessing plasma Aβ42/Aβ40 ratio seems promising for non-invasive cost-effective detection of brain accumulation. This approach involves some challenges, including accuracy blood-based biomarker measurements establishment clear, standardized thresholds to categorize...

Abstract Background In AD, tau pathology starts in the medial temporal lobe, including amygdala‐hippocampal complex. The amygdala is composed of subnuclei that until recently could not be distinguished in‐vivo. This has been achieved and implemented FreeSurfer 7. We aimed to investigate relative atrophy AD non‐AD disorders, evaluate association with tauopathy. Methods recruited 131 participants who underwent 3D‐T1 brain MRI 18 F‐MK6240 tau‐PET. Amyloid status (A‐/A+) was determined using...

Abstract Background Brain hypometabolism in the absence of tauopathy may indicate presence non‐AD pathologies. We aimed to investigate mismatch between regional tau pathology and brain metabolism characterize profile patients suspected have co‐pathologies. Method Sixty‐one clinically impaired patients, attending Memory Clinic, performed both a [18F]‐Fluorodeoxyglucose‐PET assess [18F]‐MK6240 Tau‐PET estimate burden. To compare these images, we normalized them using data from normal older...

Abstract Background Brain hypometabolism in the absence of tauopathy may indicate presence non‐AD pathologies. We aimed to investigate mismatch between regional tau pathology and brain metabolism characterize profile patients suspected have co‐pathologies. Method Sixty‐one clinically impaired patients, attending Memory Clinic, performed both a [18F]‐Fluorodeoxyglucose‐PET assess [18F]‐MK6240 Tau‐PET estimate burden. To compare these images, we normalized them using data from normal older...